NCT00102245 is a clinical trial in Hemoglobinopathies, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Who is sponsoring NCT00102245?

NCT00102245 is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

What condition does NCT00102245 study?

NCT00102245 studies Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias.

Is NCT00102245 still recruiting?

NCT00102245 is currently terminated. Last updated 14 February 2018.

Last reviewed 2018-02-14 · How we verify

NCT00102245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

Terminated Last updated 14 February 2018

What this trial tests

trial in Hemoglobinopathies in 334 participants. Terminated before completion.

Timeline

18 January 2005

4 August 2017

Quick facts

Lead sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	334
Start date	18 January 2005
Estimated completion	4 August 2017
Sites	1 location across United States

Conditions studied

Hemoglobinopathies — all drugs for Hemoglobinopathies →
Hemolysis — all drugs for Hemolysis →
Iron Deficiency and Overload — all drugs for Iron Deficiency and Overload →
Anemias — all drugs for Anemias →

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who can join

1 and older, any sex, with Hemoglobinopathies or Hemolysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will examine blood for factors that may cause or prevent diseases involving iron or red blood cells. Iron is an important nutrient for human health that is needed to produce red blood cells. Red blood cells carry oxygen to body tissues. A better understanding of iron and red blood cells may help lead to better treatment of several diseases including anemia. Patients of all ages with red cell abnormalities in the following categories may be eligible for this study: * Diseases with deficiency, overload or maldistribution of iron * Known red blood cell diseases, such as anemias and hemoglobinopathies * Red blood cell diseases of unknown cause, such as hemolysis of unknown cause * Red blood cell abnormalities with no overt clinical disease, such as hereditary persistence of fetal hemoglobin Participants undergo the following procedures: * Medical history * Physical examination * Standard medical tests related to the individual's iron or red blood cell condition Blood draw for the following purposes: * Testing for syphilis and for the hepatitis B and C, HIV, and HTLV-1viruses, and for a pregnancy test for women who can become pregnant * Research purposes. This blood is analyzed for genes, proteins, sugars, and fat molecules.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Flow cytometric immunophenotypic differentiation patterns of bone marrow eosinophilopoiesis.
Trindade CJ, Sun X, Maric D, Sharma S, et al · · 2024 · cited 3× · PMID 38666394 · DOI 10.1002/cyto.b.22174

Verify or expand the search:

Other recruiting trials for Hemoglobinopathies

Currently open trials in the same condition.

NCT06872333 — Allo HSCT for High Risk Hemoglobinopathies · Phase 2 · recruiting
NCT05236764 — Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion · NA · active not recruiting
NCT06107400 — Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease · EARLY_PHASE1 · recruiting
NCT05799118 — Study of the Role of Genetic Modifiers in Hemoglobinopathies · recruiting
NCT05477563 — Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia an · Phase 3 · recruiting

Other National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) trials

Trials by the same sponsor.

NCT07313787 — Effects of Meal Macronutrients on Postprandial Lipids · Phase 2 · not yet recruiting
NCT07388537 — Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults · not yet recruiting
NCT05713799 — Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · not yet recruiting
NCT05722210 — Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant · not yet recruiting
NCT07191561 — Hepatic Lipid Metabolism-Alcohol Use Disorder · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00102245 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Last refreshed: 14 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00102245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing